Sign in

    Evan Kane

    Research Analyst at Barclays

    Evan Kane is an analyst at Barclays, but a thorough review of available public and professional records does not uncover a verifiable LinkedIn profile, detailed career history, performance track record, or evidence of sector and company coverage under his name. There are no documented success metrics, rankings, or notable achievements attributed to Evan Kane as an equity research analyst at Barclays, nor is there confirmation of his securities licenses or FINRA registration. Without a confirmed online professional presence or supporting performance data, further detail about his specific role, expertise, or credentials is currently unavailable.

    Evan Kane's questions to RadNet (RDNT) leadership

    Evan Kane's questions to RadNet (RDNT) leadership • Q3 2024

    Question

    Evan Kane from Barclays asked about the nearly 10% sequential decrease in AI revenue from Q2 to Q3 2024, despite stable mammography volumes. He also questioned if the AI business is still on track for profitability by year-end and asked for current EBCD adoption rates on the East and West Coasts.

    Answer

    Executive Mark Stolper clarified the sequential AI revenue dip was due to a non-recurring $600,000 implementation fee in Q2; adjusting for this, AI revenue actually grew. He reaffirmed that the AI business is expected to reach profitability in Q4 2024. CEO Dr. Howard Berger reported the EBCD adoption rate is approaching 45% on the East Coast and is around 30% on the West Coast, with the West Coast figure impacted by ongoing negotiations with capitated providers.

    Ask Fintool Equity Research AI